Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Apr;41(4):541–552. doi: 10.1038/bjc.1980.96

Immunotherapy of primary methylcholanthrene-induced mouse tumours by intratumoral BCG.

N Creau-Goldberg, J C Salomon
PMCID: PMC2010287  PMID: 7387852

Abstract

Tumours were induced s.c. in C3H/uip, SJL/uip, DBA/2 uip, C57BL/6 uip and BDF1 mice by different doses of methylcholanthrene (MCA) diluted in oil: 1 mg, 0.1 mg and 0.01 mg. In each mouse strain, tumour frequency showed a different decreasing pattern in relation to the decreasing dose of MCA. Tumour latent period (LP) increased between the 1mg and 0.1mg doses of MCA, but the 0.01mg dose induced tumours with a similar or shorter LP than those tumours induced by 1 mg. Half of the tumours were treated with two injections of intratumoral (IT) BCG. The strains of mice differed in their sensitivity to this treatment, but only tumours induced by 0.01 mg MCA were sensitive to IT BCG. The induction of tumours by MCA pellets gave similar results. After transplantation of the untreated tumours, very few were cured by BCG treatment. Analysis of the role of tumour LP, growth rate and immunogenicity favours a slow growth rate as the most important characteristic for BCG sensitivity of the primary tumour. The tumours induced by 0.01 mg MCA were less immunogenic than those induced by 1 mg MCA, but the difference was not significant. This finding permits us to exclude an important role for tumour immunogenicity in the sensitivity of the primary tumour to BCB.

Full text

PDF
541

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W., Pimm M. V. BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer. 1973 Jan;27(1):48–54. doi: 10.1038/bjc.1973.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baldwin R. W., Pimm M. V. BCG immunotherapy of rat tumors of defined immunogenicity. Natl Cancer Inst Monogr. 1973 Dec;39:11–19. [PubMed] [Google Scholar]
  3. Baldwin R. W., Pimm M. V. Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol. 1971 Nov;16(9):875–881. [PubMed] [Google Scholar]
  4. Bartlett G. L. Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst. 1972 Aug;49(2):493–504. [PubMed] [Google Scholar]
  5. Bartlett G. L., Kreider J. W., Purnell D. M. Immunotherapy of cancer in animals: models or muddles? J Natl Cancer Inst. 1976 Feb;56(2):207–210. doi: 10.1093/jnci/56.2.207. [DOI] [PubMed] [Google Scholar]
  6. Bast R. C., Bast B. S. Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci. 1976;277(00):60–93. doi: 10.1111/j.1749-6632.1976.tb41692.x. [DOI] [PubMed] [Google Scholar]
  7. CHOUROULINKOV I., RIVIERE M. R., GUERIN M. [Influence of the strain of mouse on the carcinogenic power of methylcholanthrene in different doses]. C R Seances Soc Biol Fil. 1961;155:2136–2139. [PubMed] [Google Scholar]
  8. Chassoux D., Salomon J. C. Therapeutic effect of intratumoral injection of bcg and other substances in rats and mice. Int J Cancer. 1975 Oct 15;16(4):515–525. doi: 10.1002/ijc.2910160402. [DOI] [PubMed] [Google Scholar]
  9. FOLEY E. J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953 Dec;13(12):835–837. [PubMed] [Google Scholar]
  10. Lagrange P. H. Comparative studies of different strains of BCG vaccine in mice: T-cell dependent immune responses. Dev Biol Stand. 1977 Apr 13;38:223–229. [PubMed] [Google Scholar]
  11. Lynch N. R., Salomon J. C. Passive local anaphylaxis: demonstration of antitumor activity and complementation of intratumor BCG. J Natl Cancer Inst. 1977 Apr;58(4):1093–1098. doi: 10.1093/jnci/58.4.1093. [DOI] [PubMed] [Google Scholar]
  12. Meltzer M. S. Tumoricidal responses in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice. Cell Immunol. 1976 Mar 1;22(1):176–181. doi: 10.1016/0008-8749(76)90018-6. [DOI] [PubMed] [Google Scholar]
  13. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  14. Prehn R. T. Relationship of tumor immunogenicity to concentration of the oncogen. J Natl Cancer Inst. 1975 Jul;55(1):189–190. doi: 10.1093/jnci/55.1.189. [DOI] [PubMed] [Google Scholar]
  15. Slaga T. J., Bowden G. T., Scribner J. D., Boutwell R. K. Dose-response studies on the ability of 7,12-dimethylbenz(alpha)anthracene and benz(alpha)anthracene to initiate skin tumors. J Natl Cancer Inst. 1974 Nov;53(5):1337–1340. doi: 10.1093/jnci/53.5.1337. [DOI] [PubMed] [Google Scholar]
  16. Tanaka T. Effect of intratumor injection of live BCG on 3-methylcholanthrene-induced tumors of primary and early transplant generations in mice. Gan. 1974 Apr;65(2):145–151. [PubMed] [Google Scholar]
  17. Tokunaga T., Yamamoto S., Nakamura R. M., Kataoka T. Immunotherapeutic and immunoprophylactic effects of BCG on 3-methylcholanthrene-induced autochthonous tumors in Swiss mice. J Natl Cancer Inst. 1974 Aug;53(2):459–463. doi: 10.1093/jnci/53.2.459. [DOI] [PubMed] [Google Scholar]
  18. Wolfe S. A., Tracey D. E., Henney C. S. BCG-induced murine effector cells. II. Characterization of natural killer cells in peritoneal exudates. J Immunol. 1977 Sep;119(3):1152–1158. [PubMed] [Google Scholar]
  19. Zbar B., Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science. 1971 Apr 16;172(3980):271–273. doi: 10.1126/science.172.3980.271. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES